Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 38175817
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L. Wagner NB, et al. Among authors: terheyden p. Eur J Cancer. 2024 Jan;196:113425. doi: 10.1016/j.ejca.2023.113425. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039778 Free article.
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
Kähler KC, Debus D, Schley G, Göppner D, Hassel JC, Meier F, Terheyden P, Stadler R, Tüting T, Kaatz M, Hoff NP, Masoudi E, Zdanowicz-Specht A, Nguyen MT, Mohr P. Kähler KC, et al. Among authors: terheyden p. Melanoma Res. 2024 Feb 1;34(1):44-53. doi: 10.1097/CMR.0000000000000908. Epub 2023 Nov 13. Melanoma Res. 2024. PMID: 37962220 Free PMC article.
Ring-shaped plaque on the face.
Riemann S, Langan EA, Terheyden P, Boch K. Riemann S, et al. Among authors: terheyden p. Skin Health Dis. 2023 Jul 26;3(5):e272. doi: 10.1002/ski2.272. eCollection 2023 Oct. Skin Health Dis. 2023. PMID: 37799375 Free PMC article.
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel JC, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt MV, Kiecker F, Haferkamp S, Gebhardt C, Simon JC, Grabbe S, Loquai C. Haist M, et al. Among authors: terheyden p. J Immunother Cancer. 2023 Sep;11(9):e007630. doi: 10.1136/jitc-2023-007630. J Immunother Cancer. 2023. PMID: 37730278 Free PMC article.
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Welzel J, Engel DR, Kreft S, Sucker A, Lodde G, Krefting F, Stoffels I, Klode J, Roesch A, Zimmer L, Livingstone E, Hadaschik E, Becker JC, Weichenthal M, Tasdogan A, Schadendorf D, Ugurel S. Placke JM, et al. Among authors: terheyden p. EBioMedicine. 2023 Oct;96:104774. doi: 10.1016/j.ebiom.2023.104774. Epub 2023 Sep 4. EBioMedicine. 2023. PMID: 37660535 Free PMC article.
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E, Gogas H, Kandolf-Sekulovic L, Meier F, Eigentler TK, Ziemer M, Terheyden PAM, Gesierich AH, Herbst RA, Kähler KC, Ziogas DC, Mijuskovic Z, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Grob JJ, Kiecker F, Utikal J, Windemuth-Kieselbach C, Eckhardt S, Zimmer L, Schadendorf D. Livingstone E, et al. Among authors: terheyden pam. Eur J Cancer. 2023 Sep;190:112941. doi: 10.1016/j.ejca.2023.112941. Epub 2023 Jun 15. Eur J Cancer. 2023. PMID: 37482012 Clinical Trial.
147 results